Introduction
============

Uveitis is one of the major ocular disorders that results in preventable blindness.^[@B1]^ It contains inflammatory pathologies affecting the uveal tract of the eye and it can also involve the vitreous body, optic nerve and retina.^2^ Uveitis can lead to cystoid macular edema among other complications resulting in reduced vision and even permanent visual loss.^[@B2]^ Although the actual pathogenic mechanisms underlying uveitis are defectively recognized, cytokines which are thought of as essential mediators of immunologic and inflammatory reactions, seem to be associated with this disorder. Several cytokines including tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), IL-2, IL-6 and interferon-γ have been recognized in ocular material received from patients with uveitis.^[@B3]-[@B6]^ A definitive or effective treatment modality for uveitis has not yet been introduced. The development of a perfect treatment modality aiming to control inflammation and reduce recurrence in patients with uveitis remains a significant research goal.^7^

The TNF-α is a significant element in the pathogenesis of uveitis^[@B8]^ and many studies have suggested that TNF-α is also involved in the development of endotoxin-induced uveitis (EIU).^[@B6],[@B9]^

Pentoxifylline (PTX) is a methylxanthine derivative and a non-selective phosphodiesterase inhibitor with hemorrheological property.^[@B10]^ The PTX has also been found to increase leukocyte deformability, inhibit neutrophil adhesion and activation and inhibit TNF-α production.^[@B11]^ Furthermore, different studies have shown that PTX enhances polymorphonuclear cell motility and chemotaxis.^[@B12]^ The mechanism of action might be multifactorial.^[@B13]^ The PTX has garnered increased attention as it had been demonstrated to inhibit or attenuate the release of TNF-α induced by lipopolysaccharide (LPS) *in vitro* and *in vivo* by elevating intracellular levels of cAMP.^[@B14]^ The TNF-α is an essential inflammatory mediator and is known to modulate synthesis of different cytokines and other inflammatory molecules.^[@B15]^ Thus, inhibition of TNF- α could eventually result in a reduction of other inflammatory mediators such as IL-1, IL-6 and IL-8.^[@B16]^ PTX is not merely able to prevent the release of TNF-α, but can also influence the secretion of IL-1B, IL- 6 and IL-8.^[@B17]^

There are few studies that have investigated the effect of systemic treatment of PTX in uveitis in human and experimental models.^[@B18]-[@B20]^ Therefore, in view of the inhibitory activity of PTX on TNF-α and the potential role of PTX in the treatment of human uveitis, the present study was designed to investigate the clinical and histopathological effects of intravitreal injection of PTX on ocular inflammation in an experimental EIU.

Materials and Methods
=====================

The study was conducted on 52 New Zealand white rabbits from both sexes weighting between 2.50 and 3.80 kg. All rabbits were treated in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research and all animal experiments were approved by the State Committee on Animal Ethics, Shiraz University (IACUC No: 4687/63). The animals were kept under standard laboratory conditions at 21 ˚C and 50.00% humidity and fed rabbit commercial food in a 12-hr light/12-hr dark cycle and water was available *ad libitum*. All rabbits were examined by slit lamp microscope and indirect ophthalmoscopy before the intravitreal injections. Only left eye of each animal was used in this experiment. The rabbits were randomly divided into six groups: the first group (n = 8) received 0.10 mL balanced salt solution (BSS) intravitreally, the second group (n = 8) received 2.00 μg 0.05 mL^-1^ *Salmonella* *typhimurium*LPS (L6511; Sigma, St. Louis, USA) plus 0.05 mL BSS, the third group (n = 12) received 100 μg 0.05 mL^-1^ PTX (Sigma) plus 2.00 μg 0.05 mL^-1^ LPS, the fourth group (n = 12) received 500 μg 0.05 mL^-1^ PTX plus 2.00 μg 0.05 mL^-1^ LPS, the fifth group (n = 6) received 100 μg 0.05 mL^-1^ PTX plus 0.05 mL BSS and sixth group (n = 6) received 500 μg 0.05 mL^-1^ PTX plus 0.05 mL BSS. Injections were made under aseptic condition 2.50 mm posterior to the limbus through a 31-gauge needle. Topical ciprofloxacine 0.30% (Sina Darou, Tehran, Iran) and timolol 0.50% (Sina Darou) were applied before and after the injections and the eyes were examined by indirect ophthalmoscopy for intra-operative complications. All injections were done by a single investigator in a masked fashion. All procedures were performed under general anesthesia with an intra-muscular injection of a mixture of ketamine hydrochloride 10.00% (35 mg kg^-1^, Alfasan, Woerden, Netherlands) and xylazine hydrochloride 2.00% (5.00 mg kg^-1^, Alfasan) and acepromazine 1.00% (0.70 mg kg^-1^, Alfasan). Tetracaine eye drop (0.50%; Sina Darou) was used for topical anesthesia. All rabbits were observed for signs of clinical inflammation by slit-lamp biomicroscope (Sl 115; Carl Zeiss, Oberkochen, Germany) in upward position consciously without any sedation. The degree of anterior chamber inflammation was clinically assessed in a masked manner by two investigators 24 hr after the intravitreal injections and then every other day up to seventh post-injection day. Two rabbits were died maybe because of dysbiosis due to gastrointestinal stasis as a result of stress or even pain on the third and fifth post-injection days and were excluded from groups 2 and 1, respectively. All eyes were evaluated for vascular, pupillary, hypopyon and exudative inflammatory signs. The intensity of intraocular inflammation signs was graded using a clinical scoring system described previously.^[@B21]^

Iris hyperemia was scored for absence (0), mild (1), moderate (2) or severe (3); pupil was scored as miotic (0) or normal (1); anterior chamber flare was scored as absence (0), mild (1) or severe (2) and hypopyon was scored for none (0) or positive (1). The maximum possible uveitis score--that is the sum of the four parameter scores--was 7.

On the seventh post intravitreal injection day, the rabbits were euthanized by an intraperitoneal injected overdose of sodium pentobarbital (150 mg kg^-1^; Sigma). Immediately, the eyes were enucleated. Whole globes were fixed in 10% formaldehyde for three days and processed in a standard manner for light microscope using hematoxylin and eosin. Pupillo-optic sections were made through the pupillary-optic nerve axis and observed under microscope. Ophthalmic pathologist counted all infiltrating inflammatory cells in two random, noncontiguous fields at 200× magnification in both anterior (anterior chamber, iris and iris-ciliary body) and posterior segment sections (vitreous and retina). A semi-logarithmic grading scale from Verma *et al.* was used.^[@B22]^ The grades were as follows: grade 0 = no cells per field; grade 1 = 1 to 10 cells per field; grade 2 = 11 to 30 cells per field; grade 3 = 31 to 100 cells per field and grade 4 = 101 to 300 cells per field. The mean histopathological inflammation intensity score including anterior chamber, iris, ciliary body, vitreous and retina was used for statistical analyses.

A Kruskal Wallis test was used to compare the histopathological and clinical scores and *p* value of less than 0.05 was considered significant. Mann-Whitney U test with Bonferroni correction was used to detect which pairs had significant difference and value of *p*\< 0.01 was considered significant. Statistical analysis was performed using SPSS (version 21.0; SPSS Inc., Chicago, USA).

Results
=======

**Clinical severity score.**On the first up to seventh post-injection days in all groups except group 1, some degrees of ocular inflammation with signs of iris hyperemia, miosis and anterior chamber flare were seen. In addition, on the first, third, fifth and seventh post-injection days, group 1 rabbits showed no clinical sign of ocular inflammation at any time point (median clinical severity scores were 0). Comparison of median clinical severity score according to slit lamp examination grading between the six groups on the first, third, fifth and seventh post-injection days is presented in [Table 1](#T1){ref-type="table"}. The comparison of clinical severity score between groups 1 and 2 on the fifth and seventh post-injection days showed a clinically significant difference (*p*= 0.002 and *p*= 0.001, respectively). In addition, the comparison of clinical severity score between groups 1 and 3, 1 and 4, 1 and 5 and 1 and 6, on the third, fifth and seventh post-injection days showed more severe ocular inflammation and clinically significant different inflammation (*p*\< 0.01).

###### 

Comparison of clinical uveitis scores according to slit lamp examination grading between the experimental groups. Data are presented as median (range).

  **Groups**                                                   **Number**   **Day 1**       **Day 3**       **Day 5**       **Day 7**
  ------------------------------------------------------------ ------------ --------------- --------------- --------------- ---------------
  **NS**                                                       8            0 (0 to 2)      0 (0 to 3)      0 (0 to 1)      0 (0 to 0)
  **NS+LPS**                                                   8            2.00 (0 to 4)   2.00 (0 to 3)   2.00 (1 to 3)   2.00 (1 to 3)
  **LPS+PTX 100**                                              12           2.00 (0 to 4)   3.50 (1 to 7)   3.00 (1 to 7)   3.00 (0 to 7)
  **LPS+PTX 500**                                              12           2.00 (0 to 6)   1.50 (0 to 7)   1.50 (0 to 7)   1.00 (0 to 7)
  **NS+PTX100**                                                6            2.00 (2 to 3)   3.50 (2 to 4)   4.00 (3 to 5)   4.00 (2 to 5)
  **NS+PTX 500**                                               6            2.00 (0 to 4)   4.00 (2 to 7)   4.00 (2 to 7)   4.00 (0 to 7)
  ***p*** **value** [\*](#TFN1){ref-type="table-fn"}                        0.094           0.002           0.001           0.002
  **Pair-wise comparison** ^[†](#TFN2){ref-type="table-fn"}^                                                                
  **NS vs NS+LPS**                                                                                          0.002           0.001
  **NS vs LPS+PTX 100**                                                                     0.001           \< 0.001        0.001
  **NS vs LPS+PTX 500**                                                                     0.009           0.002           0.001
  **NS vs NS+PTX 100**                                                                      0.008           0.004           0.002
  **NS vs NS+PTX 500**                                                                      0.004           0.002           0.007

NS: Normal saline; LPS: Lipopolysaccharid; PTX: Pentoxifylline;

Calculated by the Kruskal-Wallis test (*p*\< 0.05 considered as significant);

Calculated by the Mann-Whitney U test (*p*\< 0.01 considered as significant).

**Histopathological examination.**Median, first and third quartile of histopathological inflammation intensity scores in six groups are shown in [Fig. 1](#F1){ref-type="fig"}. The mean inflammation intensity scores including anterior chamber, iris, ciliary body, vitreous and retina in groups 5 and 6 were significantly higher than group 1 (*p*= 0.008 and *p*= 0.01, respectively). In addition, the mean inflammation intensity scores in groups 3, 4, 5 and 6 were significantly higher than group 2 (*p*= 0.001, *p*= 0.007, *p*= 0.001 and *p*= 0.007, respectively), so histopathological examination ([Figs. 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}) revealed that PTX can induce inflammation.

![Box-and whisker plot of histopathology average of inflammation intensity scores in six experimental groups are shown in box plot. NS: Normal saline; LPS: Lipopolysaccharid; PTX: Pentoxifylline. \* Asterisk indicates significant difference between main treatments vs NS and LPS+NS (*p*\< 0.05).](vrf-9-239-g001){#F1}

![Inflammatory cell infiltration (arrowheads) and ciliary body congestion of hematoxylin-eosin--stained photomicrographs (100×) from anterior chamber angle appearance in histological sections of LPS (A), PTX 500 µg (B) and LPS+PTX 500 µg (C) groups are noted.](vrf-9-239-g002){#F2}

![Vitreous infiltration with inflammatory cells (arrowheads) of hematoxylin-eosin--stained photomicrographs (400×) from retina appearance in histological sections of LPS (A), PTX 500 µg (B) and LPS+PTX 500 µg (C) groups are noted.](vrf-9-239-g003){#F3}

Discussion
==========

The EIU is a well-known animal model for evaluating the efficacy of treatment for ocular inflammation.^[@B23]^ Although many pro-inflammatory mediators have been involved in the pathogenesis of uveitis, it has been proposed that TNF-α plays a critical role.^[@B24]^ In patients with uveitis including Behcet's disease, TNF-α concentrations are increased in serum and aqueous humour.^[@B25]^ Due to its critical role in inflammation, inhibition of TNF-α activity might be effective in the treatment of uveitis.^[@B8]^

Modulation of cytokines is mainly performed by applying natural inhibitors such as antibodies, receptor antagonist and soluble receptors. Another method is use of drugs that inhibit cytokine synthesis.^[@B26]^ The PTX is a phosphodiestrase inhibitor that is also able to prevent cytokine production, because of its ability to increase cAMP levels.^27^ This drug has been beneficially used in cerebrovascular disorders and it is proved to inhibit the production of TNF-α, IL-1, IL-6 and IL-8. Thus, it decreases inflammatory cytokines production by phagocytes and modulates their effects on neutrophil function.^[@B18]^ The PTX has been identified as having many ocular effects. These include increased pulsatile ocular blood flow, increased blood flow velocity in retinal vessels, protection against retinal ischemia/ reperfusion damage and increased choroidal perfusion in eyes with ocular hypotension ^[@B28],[@B29]^ Throughout the last decade, there has been much interest about using the vitreal cavity for delivery of therapeutic agents to the posterior segment of the eye. The blood--retinal barrier is bypassed and higher concentrations can be attained within the ocular tissues with little systemic exposure.^[@B30]^ Due to inhibitory action of PTX on TNF-α synthesis, we evaluated clinical and histopathological effects of intravitreal injection of PTX in an experimental model of EIU. Our results revealed that PTX treatment considerably induces and exacerbates ocular inflammation. We used two different dosages of PTX to assess its effect on the severity of uveitis and evaluate whether higher dosage would have better clinical and histophatological outcomes in management of an experimental model of uveitis. According to our results, when clinical and histopathological examination scores were compared, no significant difference between different dosages of PTX was found. According to the literature, PTX was administered mostly in the systemic route for treatment of the uveitis.^[@B20],[@B26]^ In two studies, improvement of anterior ocular involvement by systemic administration of PTX in control of uveitis in patients with Bechet\'s disease was achieved, however, De Vos *et al.* and Avunduk *et al.* have found that systemic PTX treatment has no influence on the severity of uveitis in rats.^[@B20],[@B26]^ One study that has evaluated intravitreal injection of PTX as a part of a study without any serial clinical and histopathological examinations for evaluation of inflammation, showed that intravitreal injection of PTX in three different doses (20 μg, 100 μg and 500 μg) in combination with LPS has aggravated the uveitis which is similar to what we observed in the current study.^[@B26]^ To the best of our knowledge, there is no report about evaluation of clinical and histopathological effects of intravitreal injection of PTX in an experimental model of EIU in rabbits. The results of our study demonstrated that intravitreal administration of PTX does not have therapeutic effects, but inversely it induces ocular inflammation. The induction of ocular inflammation by PTX could be attributed to its effect on breakdown of blood-ocular barrier^[@B31]^ or chemotaxis of polymorpho-nuclear leukocytes.^[@B32]^ Other explanations such as drug-induced uveitis due to possible immunogenic effect of intra-ocular injection of PTX could be considered. Drug-induced uveitis after treatment with various TNF-α inhibitors has been reported previously, but their exact mechanism is not clear.^[@B33]^ The inverse relationship between TNF-α and the pro-inflammatory cytokines such as interferon (α and γ) and changes in cytokine balance in response to TNF-α inhibition have been suggested to elicit immune cell activation, autoantibody formation and immune complex deposition, finally leading to the development of inflammatory effects.^[@B34],[@B35]^

Although in many studies intravitreal injections of LPS and drug administrations were performed at the same time,^[@B20],[@B26]^ as we did, it would be more effective to inject PTX intravitreally 24 hr after LPS injection. Furthermore, equal number of participants in each group is recommended which can decrease bias on the results and conclusion. Fundoscopy was not performed, therefore there is no information about posterior segment inflammation by neither examination nor fluorescein angiography. In addition, retinal toxicity is a primary concern in case of using intravitreal drugs. Electroretinography for investigation of probable retinal toxicity of PTX on the posterior segment and fluorescein angiography for the evaluation of vasculitis as a sign of posterior segment inflammation are recommended.

In conclusion, although the result of our experiment revealed that intravitreal injection of PTX was not effective in treatment of uveitis, further preclinical and clinical studies are warranted in order to obtain a more robust conclusion about the use of systemic and intravitreal injections of PTX in management of patients with uveitis.

We are grateful to Dr. Mahjoob Vahedi and Mr. Omid Koohi for their assistance and cooperation at the Laboratory Animal Center of Shiraz University of Medical Sciences during this study.

Conflict of interest
====================

The authors declare no conflict of interest.
